NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD
22.84
+0.59 (+2.65%)
The current stock price of GMAB is 22.84 USD. In the past month the price increased by 14.6%. In the past year, price decreased by -12.79%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.45 | 334.73B | ||
AMGN | AMGEN INC | 14.13 | 157.78B | ||
GILD | GILEAD SCIENCES INC | 14.22 | 136.94B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.95B | ||
REGN | REGENERON PHARMACEUTICALS | 11.82 | 56.53B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.44B | ||
ARGX | ARGENX SE - ADR | 100.08 | 35.14B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.74 | 28.50B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
NTRA | NATERA INC | N/A | 22.56B | ||
BIIB | BIOGEN INC | 8.56 | 19.85B | ||
INSM | INSMED INC | N/A | 16.56B |
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
GENMAB A/S -SP ADR
Carl Jacobsens Vej 30
Valby 1560 DK
CEO: Jan G. J. van de Winkel
Employees: 2682
Phone: 4570202728
The current stock price of GMAB is 22.84 USD. The price increased by 2.65% in the last trading session.
The exchange symbol of GENMAB A/S -SP ADR is GMAB and it is listed on the Nasdaq exchange.
GMAB stock is listed on the Nasdaq exchange.
29 analysts have analysed GMAB and the average price target is 120.41 USD. This implies a price increase of 427.19% is expected in the next year compared to the current price of 22.84. Check the GENMAB A/S -SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GENMAB A/S -SP ADR (GMAB) has a market capitalization of 14.07B USD. This makes GMAB a Large Cap stock.
GENMAB A/S -SP ADR (GMAB) currently has 2682 employees.
GENMAB A/S -SP ADR (GMAB) has a support level at 21.04 and a resistance level at 23.71. Check the full technical report for a detailed analysis of GMAB support and resistance levels.
The Revenue of GENMAB A/S -SP ADR (GMAB) is expected to grow by 15.81% in the next year. Check the estimates tab for more information on the GMAB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GMAB does not pay a dividend.
GENMAB A/S -SP ADR (GMAB) will report earnings on 2025-08-07, before the market open.
The PE ratio for GENMAB A/S -SP ADR (GMAB) is 11.71. This is based on the reported non-GAAP earnings per share of 1.95 and the current share price of 22.84 USD. Check the full fundamental report for a full analysis of the valuation metrics for GMAB.
The outstanding short interest for GENMAB A/S -SP ADR (GMAB) is 0.46% of its float. Check the ownership tab for more information on the GMAB short interest.
ChartMill assigns a technical rating of 6 / 10 to GMAB. When comparing the yearly performance of all stocks, GMAB is a bad performer in the overall market: 63.62% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to GMAB. While GMAB has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months GMAB reported a non-GAAP Earnings per Share(EPS) of 1.95. The EPS increased by 48.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 29.99% | ||
ROA | 36.16% | ||
ROE | 44.97% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 77% to GMAB. The Buy consensus is the average rating of analysts ratings from 29 analysts.
For the next year, analysts expect an EPS growth of -12.51% and a revenue growth 15.81% for GMAB